Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May;10(5):2148–2162. doi: 10.21037/tlcr-21-214

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Translational Lung Cancer Research. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Treatment outcome of ICIs according to COPD severity. (A) Kaplan-Meier curve of OS by COPD severity. (B) Kaplan-Meier analysis of the PFS probability by COPD severity. Risk group stratification within COPD severity. Those with moderate and severe COPD tended to have better OS (553 vs. 495 days, P=0.54) and PFS (278 vs. 189 days, P=0.4) as compared to the non-COPD group. GOLD 1, mild COPD; GOLD 2, moderate COPD; GOLD 3, severe COPD; ICI, immune checkpoint inhibitor; COPD, chronic obstructive pulmonary disease; OS, overall survival; PFS, progression-free survival.